ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 652

Clinical Relevance According to Staining Patterns and Titers of Antinuclear Antibody

Mi Ryoung Seo1, Ji Na Yeo 2, Hee Jung Ryu 3, Hyo-Jin Choi 3 and Han Joo Baek 3, 1, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, 2Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, 3Division of Rheumatology / Department of Internal Medicine / Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Antinuclear antibodies (ANA), pattern, prevalence and cytoplasmic, titer

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Immunofluorescent antinuclear antibody (ANA) test using HEp-2 cells still plays an important role in the diagnosis of autoimmune diseases. The aim of this study was to investigate the clinical relevance of ANA according to titers and patterns.

Methods: We identified patients who were newly positive in the ANA test between December 2010 to November 2016, and collected data such as, diagnosis, ANA titer and pattern, and specific autoantibody test results.  

Results: In total, 7591 patients were included in this study. The average age was 51 (interquartile range (IQR): 35-63) years, and 69.4% were women. Figure 1 showed the patient distribution by ANA titer and pattern. The diseases with a difference in prevalence according to ANA titer were systemic lupus erythematosus (SLE), Sjögren syndrome (SjS), polymyositis/dermatomyositis (PM/DM), systemic sclerosis (SSc), autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), liver cirrhosis, hemolytic anemia, immune thrombocytopenic purpura, interstitial lung disease (ILD), chronic obstructive pulmonary disease/bronchiectasis (COPD/BE), cerebrovascular accident, and crystal induced arthropathy (CIA).  A multivariable analysis was conducted to determine whether ANA titer was an independent factor. As a result, diseases with increased prevalence with increasing ANA titer were SLE, SjS, PM/DM, SSc, AIH, PBC, and ILD, and the opposite result showed in COPD/BE and CIA (Figure 2).  

SLE was the most prevalent in patients with mixed pattern of nuclear and cytoplasmic (6.4% in ≥1:40, 40% in ≥1:2560). SjS and SSc showed the same results (SjS: 1.9% in ≥1:40, 10% in ≥1:2560, SSc: 0.5% in ≥1:40, 6.7% in ≥1:2560). The prevalence of PM/DM, AIH, PBC and ILD was highest in mixed pattern of nuclear and cytoplasmic in all patients, but it was highest in cytoplasmic pattern from 1:160 or more of ANA titer.

Conclusion: SLE, SjS, PM/DM, SSc, AIH, PBC and ILD were the diseases in which ANA titer independently affected disease prevalence. Patients with mixed pattern of nuclear and cytoplasmic had a higher prevalence of SLE, SjS and SSc than purely nuclear pattern. It is necessary to note that the cytoplasmic pattern is accompanied by the nuclear pattern in the ANA test.


Figure 1

Figure 1. Patient distribution by ANA titer and pattern.


Figure 2

Figure 2. Disease prevalence according to ANA titer


Disclosure: M. Seo, None; J. Yeo, None; H. Ryu, None; H. Choi, None; H. Baek, None.

To cite this abstract in AMA style:

Seo M, Yeo J, Ryu H, Choi H, Baek H. Clinical Relevance According to Staining Patterns and Titers of Antinuclear Antibody [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/clinical-relevance-according-to-staining-patterns-and-titers-of-antinuclear-antibody/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-relevance-according-to-staining-patterns-and-titers-of-antinuclear-antibody/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology